CS 01 - Zhongshan Constimulus Bio
Alternative Names: CS-01 - Zhongshan Constimulus BioLatest Information Update: 24 Apr 2026
At a glance
- Originator Zhongshan Constimulus Bio
- Developer Ruijin Hospital; Zhongshan Constimulus Bio
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours